Tradestie Institutional Equity Comparison Engine
XERS vs NUVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XERS Overall Edge
XERS Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XERS trades at 63.6x Forward P/E with 12.7% operating margin (+44.2% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
XERS
XERS 63.6x vs NUVB N/M Fwd P/E
Growth & Margin Winner
XERS
Op Margin 12.7% vs -61.2% ยท YoY +44.2% vs +242.6%
Momentum & Technical Winner
XERS
1Y +139.3% vs -46.9% ยท 52W Pos 97% vs 2%
Options & Structure Winner
XERS
SURGE (12th %ile IV) vs BREAKDOWN (26th %ile IV)
XERS
NASDAQ
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.97
+2.11% 1D
Market Cap
$3.0B
1M Return
+56.26%
1Y Return
+139.35%
Forward P/E
63.6x
Unified AI Score
35.7 / 100
SELL
Tech 50.0
Fund 34.0
Flow 71.0
Mom 40.0
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XERS +139.35%
NUVB -46.85%
Spread: +186.2 pp (XERS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | XERS Revenue | NUVB Revenue | XERS Op. Margin | NUVB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | $20M | N/A | -414.5% | N/A | XERS |
| FY2021 | $50M | N/A | -232.2% | N/A | XERS |
| FY2022 | $110M | N/A | -74.3% | N/A | XERS |
| FY2023 | $160M | N/A | -26.8% | N/A | XERS |
| FY2024 | $200M | $10M | -16.6% | -7527.3% | XERS |
| FY2025 | $290M | $60M | 8.5% | -338.7% | XERS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XERS | NUVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $1.3B | Larger Scale | XERS |
| Trailing P/E Ratio Valuation | 87.0x | N/M | Lower Multiple | XERS |
| Forward P/E Ratio Valuation | 63.6x | N/M | Lower Multiple | XERS |
| Revenue Growth (YoY) Growth | +44.2% | +242.6% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | 12.7% | -61.2% | Higher Margin | XERS |
| Net Profit Margin Profitability | -1.8% | -67.4% | Higher Margin | XERS |
| Return on Equity (ROE) Capital Efficiency | -27.1% | -49.1% | Higher ROE | XERS |
| 52-Week Range Position Momentum | 97% ($5โ$17) | 2% ($4โ$10) | Stronger Trend | XERS |
| Beta / 30D Volatility Risk Regime | -0.04ฮฒ ยท 104% Vol | 1.52ฮฒ ยท 55% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 35.7 / 100 (SELL) | 61.0 / 100 (BUY) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XERS vs NUVB Buy Guide
XERS
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XERS nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.